D��a mundial del corazón 2012: ���un mundo, un hogar, un corazón���

Bolet��n semanal para profesionales sanitarios de la Secretar��a General de Salud P��blica, Inclusi��n y Calidad de Vida de la Consejer��a de Salud y Bienestar Social

Celebrado el dia mundial del corazón bajo el lema ���yo trabajo con corazón���

Bolet��n semanal para profesionales sanitarios de la Secretar��a General de Salud P��blica y Participaci��n Social de la Consejer��a de Salud

Conoce tus factores de riesgo, lema del D��a Mundial del Corazón

Bolet��n semanal para profesionales sanitarios de la Secretar��a General de Salud P��blica y Participaci��n Social de la Consejer��a de Salud

Liderar con corazón

Laboratorios Ferrer

Trasplante card��aco : proceso asistencial integrado

Publicado en la p��gina web de la Consejer��a de Igualdad, Salud y Pol��ticas Sociales: www.juntadeandalucia.es/salud (Consejer��a de Salud / Profesionales / Nuestro Compromiso por la Calidad / Procesos Asistenciales Integrados)

Edge vascular response after polymer-free vs. polymer-based paclitaxel-eluting stent implantation.

BACKGROUND It is unknown if lack of polymer can provoke a different edge response in drug-eluting stents. The aim of this study was to compare edge vascular response between polymer-free paclitaxel-eluting stent (PF-PES) and polymer-based paclitaxel-eluting stents (PB-PES). METHODS���AND���RESULTS: A total of 165 eligible patients undergoing percutaneous coronary intervention were prospectively randomized 1:1 to receive either PF-PES or PB-PES. Those patients with paired intravascular ultrasound (IVUS) after procedure and at 9-month follow-up were included in this analysis.Seventy-six patients with 84 lesions, divided into PB-PES (38 patients, 41 lesions) and PF-PES groups (38 patients, 43 lesions) had paired post-procedure and 9-month follow-up IVUS and were therefore included in this substudy. There was a significant lumen decrease at the proximal edge of PF-PES (from 9.02��3.06 mm(2)to 8.47��3.05 mm(2); P=0.040), and a significant plaque increase at the distal edges of PF-PES (from 4.39��2.73 mm(2)to 4.78��2.63 mm(2); P=0.004). At the distal edge there was a significant plaque increase in the PF-PES compared to PB-PES (+8.0% vs. -0.6%, respectively; P=0.015) with subsequent lumen reduction (-5.2% vs. +6.0%, respectively; P=0.024). CONCLUSIONS PF-PES had significant plaque increase and lumen reduction at the distal edge as compared to PB-PES, probably due to difference in polymer-based drug-release kinetics between the 2 platforms.

Left ventricular assist device.

To the Editor: The value of angiotensin-converting��� enzyme (ACE) inhibitors, beta-blockers, and spironolactone has been well established by the results of numerous clinical trials. About 70 percent of the patients described by Rose et al. were treated with ACE inhibitors or angiotensin II���receptor antagonists; 35 to 40 percent received spironolactone, and only about 20 percent received beta-blockers. Thus, this population cannot have been considered to be optimally treated from the point of view of medical therapy.